Small Bowel Adenocarcinoma
Research activity includes small bowel adenocarcinoma after surgical resection, with interest in adjuvant chemotherapy and postoperative treatment strategies for stage I-IV disease.
- Post-operative fluoropyrimidine therapy
- Oxaliplatin-based combination chemotherapy
- Adjuvant treatment selection
The sponsor is involved in evaluating treatment options that may influence recurrence control and long-term management in resected small bowel adenocarcinoma.
Metastatic Pancreatic Ductal Adenocarcinoma
Clinical interest extends to metastatic pancreatic ductal adenocarcinoma, particularly after prior exposure to gemcitabine-based therapy and in the setting of progressive disease.
- 5-FU-based regimens
- Nal-IRI combinations
- NALIRINOX treatment approaches
This area reflects focus on systemic therapy options for advanced pancreatic cancer with limited remaining treatment choices.
Digestive Oncology
The sponsor’s portfolio is centered on digestive oncology, with emphasis on malignant diseases of the gastrointestinal tract and treatment pathways that address both localized and advanced settings.
- Gastrointestinal adenocarcinoma
- Post-surgical oncology care
- Systemic anticancer therapy
Research activity is aligned with clinical decision-making for tumors arising in the digestive system, especially where standard options remain constrained.
